Source link : https://www.newshealth.biz/health-news/what-now-for-factor-xi-inhibitors-in-af/
Factor XI inhibition was potentially the Goldilocks anticoagulant target with the promise of a reduction in thrombotic risk without a significant increase in bleeding. The early phase 2 data were encouraging, and the trials in orthopedic patients looked good. Then the phase 3 OCEANIC-AF, trial comparing the novel factor XI inhibitor asundexian (Bayer) vs the direct-acting […]
Author : News Health
Publish date : 2024-12-11 11:55:00
Copyright for syndicated content belongs to the linked Source.
inHealth